{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 56,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a comparative framework to validate the efficacy of CDx-guided patient selection.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/45",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Spyre aims to develop genetic companion diagnostics across a portfolio of best-in-class therapeutics",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f84e5a5-f302-4f57-814b-fa85b852ffcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Prometheus Biosciences PRA023 TL1A UC clinical remission at 12 weeks",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "161c057b-d0c7-4b88-81b9-2bfb8a3ce48f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Roivant RVT-3101 TL1A UC clinical remission at 12 weeks",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b9f202d-a8ac-4afa-a36e-08dbafcfdc4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Company materials",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dc73569-c7bf-405e-b304-9dbe89c2d9cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Prometheus and Roivant demonstrated POC that a genetic CDx can identify responders to TL1A",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5275593-7fca-4f44-8288-f66ed2f84d3f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "d68d4fbe-faa9-4e8b-ae5e-1c71ff4c1188",
      "evidence": "The slide uses bar charts to display clinical remission data.",
      "confidence": 0.5
    },
    {
      "name": "Evidence Matrix",
      "slug": "evidence-matrix",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "6a669d76-d616-4a23-adee-9f8eb29e3b12",
      "evidence": "The slide presents clinical data in a table format to support the proof of concept (POC) for a genetic CDx.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "9ae806ff-4a3b-4a8f-accc-50ed9d6f90a8",
      "evidence": "Side-by-side comparison of two clinical trial outcomes to validate a business thesis.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 56,
      "from": 45,
      "beatId": "712c62dc-223b-4b2c-ba9f-cd5c102db383",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document calls for action, outlining the company's plans and milestones",
      "position": 5,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}